Advertisement

Comparison of Immunohistochemistry, Cytochemistry, and Flow Cytometry in AML for Myeloperoxidase Detection

  • Ankur Ahuja
  • Seema Tyagi
  • Tulika Seth
  • Hara Prasad Pati
  • GPS Gahlot
  • Preeti Tripathi
  • Venkatesan Somasundaram
  • Renu Saxena
Original Article
  • 119 Downloads

Abstract

Acute Myeloid Leukemia (AML) as per World Health Organization (WHO 2008) classification is on the basis of the antigenic characterization, enzymes restriction in the neoplastic myeloid cells and the specific translocations/mutations. AML can be assessed and differentiated by flowcytometry (FCM)/immunohistochemistry (IHC)/cytochemistry techniques. Myeloperoxidase (MPO) is an unequivocal marker to differentiate AML from the acute lymphoblastic leukemia. Despite FCM popularity, it has its limitations, in form of ‘dry-tap’, cost, and inability of being performed by retrospective analysis. IHC, though an old technique has overcome these disadvantages of FCM. Cytochemistry, on the other hand has its own advantages in being cost-effective; technically easy to do while its disadvantages are its inability to be carried out in the old samples, ‘dry-tap’ conditions in aleukemic leukemia. There has been non-uniformity in the literature among these techniques especially concerning their sensitivity for MPO. A prospective study was done at All India Institute of Medical Sciences New Delhi from 01 July 2014 to 30 Nov 2015 to include 120 diagnosed acute myeloid leukemia cases. Myeloperoxidase stain was done by cytochemistry, immunohistochemistry and flow cytometry and results were compared. There were 28 cases which showed discrepancies. Out of these 28 cases immunohistochemistry showed positivity in majority (22 cases) followed by flow cytometry (14 cases). Therefore it is important to employ more than one technique and IHC must be included for detection of MPO in all suspected cases of AML especially when negative with FCM .

Keywords

Acute myeloid leukemia (AML) Myeloperoxidase (MPO) Cytochemistry Immunohistochemistry (IHC) Flow cytometry (FMC) Bone marrow aspirate (BMA) Bone marrow biopsy (BMB) CD34 Blasts 

Notes

Acknowledgements

We acknowledge the support of our patients, as with their support the study had been feasible.

Author Contribution

AA and ST were involved in conceptualization, designing, writing and critical review of the manuscript and were responsible for overall supervision. TS, HPT, GPSG, PT and VS were involved in literature search, writing and manuscript editing. ST is the overall guarantor of the article.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Ethical Approval

The present study is in compliance with Ethical Standards.

References

  1. 1.
    Neame PB, Soamboonsrup P, Browman GP et al (1986) Classifying acute leukemia by immunophenotyping: a combined FAB immunologic classification of acute myelogenous leukemia. Blood 68:1355–1362PubMedGoogle Scholar
  2. 2.
    Bene MC, Castoldi G, Knapp W et al (1995) Proposals for the immunological classification of acute leukemia’s. European group for the immunological characterization of leukemia’s (EGIL). Leukemia 9:1783–1786PubMedGoogle Scholar
  3. 3.
    Subashchandrabose P, Madanagopaal LR, Rao TMS (2016) Diagnosis and Classification of Acute Leukemia in Bone Marrow Trephine Biopsies, Utility of a Selected Panel of Minimal Immunohistochemical Markers. IJHOSCR 10(3):138–146PubMedPubMedCentralGoogle Scholar
  4. 4.
    Peffault de Latour R, Legrand O, Moreau D, Perrot J, Blanc C, Chaoui D, Casadeall N, Marie J (2003) Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxidase in acute myeloid leukaemia: interests of a new positivity threshold. Br J Haematol 122:211–216CrossRefPubMedGoogle Scholar
  5. 5.
    Kheiri S, MacKerrell T, Bonagura V, Fuchs A, Billett H (1998) Flow cytometry with or without cytochemistry for the diagnosis of acute leukemia’s. Cytometry 34:82–86CrossRefPubMedGoogle Scholar
  6. 6.
    Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, LyonGoogle Scholar
  7. 7.
    Saravanan L, Juneja S (2010) Immunohistochemistry is a more sensitive marker for the detection of myeloperoxidase in acute myeloid leukemia compared with flow cytometry and cytochemistry. Int J Lab Hematol 32:132–136CrossRefGoogle Scholar
  8. 8.
    General Hematology Taskforce of BCSH (1994) Immunophenotyping in the diagnosis of acute leukemia’s. J Clin Pathol 47:777–781CrossRefGoogle Scholar
  9. 9.
    Prabhu M, Vandana P, Venkatesan S, Abhishek P, Rahul KS, Mandeep D, Renu S (2015) Can threshold for MPO by flow cytometry be reduced in classifying acute leukaemia? A comparison of flow cytometric and cytochemical myeloperoxidase using different flow cytometric cut-offs. Hematology 20:455–461CrossRefGoogle Scholar
  10. 10.
    Nakase K, Sartor M, Bradstock K (1998) Detection of myeloperoxidase by flow cytometry in acute leukemia. Cytometry 34:198–202CrossRefPubMedGoogle Scholar
  11. 11.
    Arber A, Snyder D, Fine M, Dagis A, Niland J, Slovak M (2001) Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia. Am J Clin Pathol 116:25–33CrossRefPubMedGoogle Scholar
  12. 12.
    Nguyen P, Olszak L, Harris N, Preffer F (1998) Myeloperoxidase detection by three-color flow cytometry and by enzyme cytochemistry in the classification of acute leukemia. Am J Clin Pathol 110:163–169CrossRefPubMedGoogle Scholar
  13. 13.
    Lepelley P, Preudhomme C, Sartiaux C, Ghevaert C, Lai J, Iaru T, Fenaux P, Cosson A (1993) Immunological detection of myeloperoxidase in poorly differentiated acute leukemia. Eur J Haematol 50:155–159CrossRefPubMedGoogle Scholar
  14. 14.
    Van der Schoot C, Daams G, Pinkster J, von Vet R, dem Borne A (1990) Monoclonal antibodies against myeloperoxidase are valuable immunological reagents for the diagnosis of acute myeloid leukemia. Br J Haematol 74:173–178CrossRefPubMedGoogle Scholar
  15. 15.
    Bain B, Barnett D, Linch D, Matutes E, Reilly J (2002) Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Hematol 24:1CrossRefGoogle Scholar
  16. 16.
    van den Ancker W, Westers TM, de Leeuw DC, van der Veeken YF, Loonen A, van Beckhoven E, Ossenkoppele GJ, van de Loosdrecht AA (2013) A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. Cytom B Clin Cytom 84B:114–118CrossRefGoogle Scholar
  17. 17.
    Jaffe E, Harris N, Stein H, Vardiman J (eds) (2001) World health organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues, chapter 4. IARC Press, LyonGoogle Scholar
  18. 18.
    Guy J, Antony-Debré I, Benayoun E, Arnoux I, Fossat C, Le Garff-Tavernier M, Raimbault A et al (2013) Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblasticleukaemia. Br J Haematol 161:551–555CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2017

Authors and Affiliations

  • Ankur Ahuja
    • 1
  • Seema Tyagi
    • 2
  • Tulika Seth
    • 2
  • Hara Prasad Pati
    • 2
  • GPS Gahlot
    • 1
  • Preeti Tripathi
    • 2
  • Venkatesan Somasundaram
    • 3
  • Renu Saxena
    • 2
  1. 1.Department of Lab Sciences and Molecular MedicineArmy Hospital (Research and Referral)New DelhiIndia
  2. 2.Department of HaematologyAll India Institute of Medical SciencesNew DelhiIndia
  3. 3.Department of PathologyArmed Forces Medical CollegePuneIndia

Personalised recommendations